Bluejay Diagnostics, Inc.

NasdaqCM BJDX

Bluejay Diagnostics, Inc. Shareholders' Equity for the quarter ending September 30, 2024

Bluejay Diagnostics, Inc. Shareholders' Equity is NA for the quarter ending September 30, 2024. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
  • Bluejay Diagnostics, Inc. Shareholders' Equity for the quarter ending September 30, 2022 was USD 13.81 M.
Key data
Date Shareholders' Equity Minority Interest Total Equity Total Stockholders Equity and Liabilities
Market news
Loading...
NasdaqCM: BJDX

Bluejay Diagnostics, Inc.

CEO Mr. Indranil Dey
IPO Date Nov. 10, 2021
Location United States
Headquarters 360 Massachusetts Avenue
Employees 10
Sector Health Care
Industries
Description

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Similar companies

NXL

Nexalin Technology, Inc.

USD 2.78

10.76%

NUWE

Nuwellis, Inc.

USD 1.05

3.96%

HSCS

Heart Test Laboratories, Inc.

USD 3.26

1.24%

IRIX

IRIDEX Corporation

USD 1.61

-1.23%

StockViz Staff

January 15, 2025

Any question? Send us an email